daclizumab

Type: Product
Name: daclizumab
First reported 13 hours ago - Updated 13 hours ago - 1 reports

Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds Slightly

Biogen Idec (NASDAQ: BIIB) moved up a bit after a Deutsche Bank analyst on Wednesday talked up prospects for one of its multiple sclerosis drug candidate.If the drug gets marketing approval "the stock could move up by $30 to $100 in a single day, by the ... [Published Benzinga.com - 13 hours ago]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Daclizumab phase 3 trial results announced

Topline results have been announced from the first phase 3 clinical trial of the drug daclizumab in relapsing remitting MS . This global trial, known as the DECIDE trial, tested the safety and effectiveness of monthly subcutaneous injections ... [Published MS News - Jun 30 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Biogen Idec Has Lagged Its Biotech Peers, Now Is The Time To Shine!

Summary The stock is fairly valued on 2015 earnings estimates and earnings growth potential. The company boasts an excellent return on assets. This company has many shots on goal with the products in the pipeline.Biogen Idec Inc. ( BIIB ) is a global ... [Published Seeking Alpha - Jun 26 2014]
First reported Jun 25 2014 - Updated Jun 26 2014 - 1 reports

AbbVie lays out rationale for merger with Shire

Despite having been turned down three times already, AbbVie is not given up on its quest to acquire Shire and has made its case for doing a deal.Last week, Shire turned down the latest offer from AbbVie worth about $46 per share and laid out plans to ... [Published Pharma Times - Jun 25 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

AbbVie lifts annual earnings guidance on strong drug pipeline

AbbVie said Monday that it expects earnings per share of between $3.06 and $3.16 for 2014, up from previous guidance in the range of $3.00 to $3.10. The company cited positive data from its experimental pipeline, including for its two oncology programmes ... [Published FirstWord Pharma - Jun 23 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 2 reports

AbbVie Lifts Full Year EPS Outlook - Update

Research-based biopharmaceutical company AbbVie, Inc. (ABBV: Quote), who last week offered to buy Irish rival Shire Plc. (SHP.L,SHPG: Quote), Monday raised the midpoint of its full-year 2014 earnings-per-share guidance by six cents, citing strong underlying ... [Published RTTNews.com - Jun 23 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Personalized therapy for multiple sclerosis (MS)

Find out about available and emerging treatment therapies for multiple sclerosis (MS).By Mayo Clinic StaffMultiple sclerosis (MS) is a chronic inflammatory central nervous system disease that causes bothersome or disabling physical symptoms, including ... [Published Mayo Clinic College of Medicine - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Treg function depleted by Daclizumab but functional activity remains

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.OBJECTIVE:Maintenance ... [Published Multiple Sclerosis Research - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 3 reports

BIOGEN IDEC : Results Announced from Phase 3 Trial of Daclizumab High Yield Process in Relapsing MS

NEW YORK , June 18 -- The National Multiple Sclerosis Society issued the following news:Results from a large-scale, Phase 3 trial suggested that Daclizumab high yield process (DAC HYP), an experimental immune-modulating therapy taken by injection every ... [Published 4 Traders - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Results Announced from Phase 3 Trial of Daclizumab High Yield Process in Relapsing MS

/About-the-Society/News/Results-Announced-from-Phase-3-Trial-of-Daclizumab ... [Published MS News - Jun 18 2014]
Entities: daclizumab, Phase III, yield
First reported Jun 16 2014 - Updated Jun 17 2014 - 12 reports

Positive Topline Phase 3 Results for Daclizumab HYP in MS

Topline results of a phase 3 trial show treatment with daclizumab high-yield process (HYP), an investigational once-a-month therapy, was superior to daily interferon β-1a (IFN β-1a) on the study's primary endpoint, with a statistically significant 45% ... [Published American Journal of Public Health - Jun 16 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Daclizumab extension study results: impact on progression confirmed

Another treatment option for RRMS. What about progressive MS? #MSBlog #MSResearch "The daclizumab extension was finally published this week in the Lancet Neurology (abstract below). I first presented the results at the last year's AAN meeting in San ... [Published Multiple Sclerosis Research - Mar 21 2014]

Quotes

If the drug gets marketing approval "the stock could move up by $30 to $100 in a single day, by the end of this year" Deutsche's Robyn Karnauskas said on CNBC's Fast Money
According to the drugmaker, the revision reflects "strong underlying business performance year to date and the expected continued positive trends over the remainder of the year."
"We look forward to seeing the complete results of this study to more fully understand the potential benefits and safety of Daclizumab high yield process for treating MS" says Timothy Coetzee , PhD, Chief, Advocacy, Services and Research Officer of the National MS Society
...Gilmore O'Neill, vice-president of global neurology clinical development at Biogen Idec, said: "As a potential once-monthly therapy with a novel mechanism of action, we believe that, if approved, DAC HYP will be an important treatment option for people living with MS." This comes after Biogen Idec received European approval for a new MS drug, Tecfidera, earlier this year

More Content

All (48) | News (29) | Reports (0) | Blogs (19) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Deutsche Bank Analyst Talks Up Biogen On CNBC; ... [Published Benzinga.com - 13 hours ago]
Daclizumab phase 3 trial results announced [Published MS News - Jun 30 2014]
Biogen Idec Has Lagged Its Biotech Peers, Now I... [Published Seeking Alpha - Jun 26 2014]
AbbVie justifies its position regarding Shire o... [Published Pharma Letter - Jun 26 2014]
AbbVie lays out rationale for merger with Shire [Published Pharma Times - Jun 25 2014]
AbbVie lifts annual earnings guidance on strong... [Published FirstWord Pharma - Jun 23 2014]
AbbVie Lifts Full Year EPS Outlook - Update [Published RTTNews.com - Jun 23 2014]
AbbVie raises EPS guidance [Published MoneyAM - Jun 23 2014]
Personalized therapy for multiple sclerosis (MS) [Published Mayo Clinic College of Medicine - Jun 20 2014]
Treg function depleted by Daclizumab but functi... [Published Multiple Sclerosis Research - Jun 19 2014]
BIOGEN IDEC : Results Announced from Phase 3 Tr... [Published 4 Traders - Jun 19 2014]
Biogen/AbbVie Presents Positive Data on Daclizumab [Published Zacks.com - Jun 18 2014]
Biogen Idec and AbbVie report positive multiple... [Published Zenopa - Jun 18 2014]
Results Announced from Phase 3 Trial of Daclizu... [Published MS News - Jun 18 2014]
2 Exciting Developments for Biogen Idec Inc. [Published Motley Fool - Jun 17 2014]
Biogen and AbbVie release Phase III data for MS... [Published Pharma Letter - Jun 17 2014]
Positive Topline Phase 3 Results for Daclizumab... [Published American Journal of Public Health - Jun 16 2014]
Biogen, AbbVie drug slows MS episodes, safety i... [Published DailyMe.Com - Jun 16 2014]
Daclizumab Superior to IFN Beta in Phase III Mu... [Published P&T Community - Jun 16 2014]
Safety issues may limit potential for Biogen, A... [Published MedCity News - Jun 16 2014]
Another eagle has landed: phase 3 daclizumab tr... [Published Multiple Sclerosis Research - Jun 16 2014]
UPDATE 1-Biogen, AbbVie drug slows MS episodes,... [Published CNBC - Jun 16 2014]
Biogen Idec, AbbVie announce positive Phase III... [Published FirstWord Pharma - Jun 16 2014]
Biogen, AbbVie drug slows MS episodes, safety i... [Published Reuters - Jun 16 2014]
Once-monthly MS drug from Biogen Idec, AbbVie c... [Published FierceBiotech - Jun 16 2014]
Biogen Idec, AbbVie Announce Positive Results F... [Published RTTNews.com - Jun 16 2014]
Biogen, AbbVie Report Positive Top-Line Results... [Published Benzinga.com - Jun 16 2014]
Biogen Idec and AbbVie Announce Positive Top-Li... [Published Business Wire Photo/Multimedia News - Jun 16 2014]
Biogen Idec and AbbVie Announce Positive Top-Li... [Published Business Wire News with Multimedia - Jun 16 2014]
Biogen Idec and AbbVie Announce Positive Top-Li... [Published Business Wire Health News - Jun 16 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Daclizumab phase 3 trial results announced [Published MS News - Jun 30 2014]
Topline results have been announced from the first phase 3 clinical trial of the drug daclizumab in relapsing remitting MS . This global trial, known as the DECIDE trial, tested the safety and effectiveness of monthly subcutaneous injections ...
Treg function depleted by Daclizumab but functi... [Published Multiple Sclerosis Research - Jun 19 2014]
Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.OBJECTIVE:Maintenance ...
Results Announced from Phase 3 Trial of Daclizu... [Published MS News - Jun 18 2014]
/About-the-Society/News/Results-Announced-from-Phase-3-Trial-of-Daclizumab ...
Another eagle has landed: phase 3 daclizumab tr... [Published Multiple Sclerosis Research - Jun 16 2014]
Daclizumab: another repurposed drug resurfaces as a treatment for MS #MSBlog #MSResearch Press Release Biogen-Idec and Abbvie have announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority ...
Biogen Idec and AbbVie Announce Positive Top-Li... [Published Business Wire Photo/Multimedia News - Jun 16 2014]
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study of Daclizumab High-Yield Process in Multiple Sclerosis ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.